NAV

INO-4800

Identification

Generic Name
INO-4800
DrugBank Accession Number
DB15693
Background

INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19.1 Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.1,2 Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.1

A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.3 A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.4

Type
Biotech
Groups
Investigational
Synonyms
  • INO-4800 DNA Coronavirus Vaccine
External IDs
  • INO 4800
  • INO-4800
  • INO4800
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, Xu Z, Walters J, Bhojnagarwala P, Yang M, Chokkalingam N, Pezzoli P, Parzych E, Reuschel EL, Doan A, Tursi N, Vasquez M, Choi J, Tello-Ruiz E, Maricic I, Bah MA, Wu Y, Amante D, Park DH, Dia Y, Ali AR, Zaidi FI, Generotti A, Kim KY, Herring TA, Reeder S, Andrade VM, Buttigieg K, Zhao G, Wu JM, Li D, Bao L, Liu J, Deng W, Qin C, Brown AS, Khoshnejad M, Wang N, Chu J, Wrapp D, McLellan JS, Muthumani K, Wang B, Carroll MW, Kim JJ, Boyer J, Kulp DW, Humeau LMPF, Weiner DB, Broderick KE: Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020 May 20;11(1):2601. doi: 10.1038/s41467-020-16505-0. [Article]
  2. Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML: Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother. 2013 Oct;9(10):2246-52. doi: 10.4161/hv.24702. Epub 2013 Jun 4. [Article]
  3. INO-4800 Phase I clinical trial NCT04336410 [Link]
  4. INOVIO Press release phase 1/2 clinical trial [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3TerminatedPreventionCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)1
1CompletedPreventionCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
1WithdrawnPreventionCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
1, 2CompletedPreventionCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at June 23, 2020 14:53 / Updated at June 24, 2020 01:34